Ultragenyx Sets $3.95 Million Price for Rare Disease Gene Therapy

3-line summary

• Ultragenyx set a $3.95 million price for its rare disease gene therapy, according to Reuters via Investing.com.
• This follows the FDA's approval of the gene therapy.

This summary is our own processing of the source article; see the source link below for full context.